Readnour Robin Shaneinsider trades
In SEC Form 4 filings, Readnour Robin Shane is listed as Director of AN2 Therapeutics, Inc. (ANTX). In the last 90 days, Readnour Robin Shane sold $104K of AN2 Therapeutics, Inc. (ANTX) on the open market and bought none. All 6 sales were reported under a 10b5-1 trading plan.
Companies and roles
| Company | Role | Transactions | Last filed |
|---|---|---|---|
| ANTXAN2 Therapeutics, Inc. | Director | 6 | Sep 11 |
Cluster buys
No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).
Form 4 historysince 2026-09-08
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| ANTXAN2 Therapeutics, Inc. | Sep 9 | Sep 11 | S | 523 | $6.02 | Sale −$3,151 | 557,467 | Yes | Form 4 |
| ANTXAN2 Therapeutics, Inc. | Sep 9 | Sep 11 | S | 585 | $6.02 | Sale −$3,524 | 624,765 | Yes | Form 4 |
| ANTXAN2 Therapeutics, Inc. | Sep 8 | Sep 8 | S | 4,725 | $6.02 | Sale −$28,436 | 557,990 | Yes | Form 4 |
| ANTXAN2 Therapeutics, Inc. | Sep 8 | Sep 8 | S | 5,294 | $6.02 | Sale −$31,861 | 625,350 | Yes | Form 4 |
| ANTXAN2 Therapeutics, Inc. | Sep 3 | Sep 8 | S | 2,877 | $6.07 | Sale −$17,463 | 562,715 | Yes | Form 4 |
| ANTXAN2 Therapeutics, Inc. | Sep 3 | Sep 8 | S | 3,223 | $6.07 | Sale −$19,563 | 630,644 | Yes | Form 4 |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.